USO 24265

ESTUDIO DE FASE II, ABIERTO Y MULTICÉNTRICO PARA EVALUAR LA OPTIMIZACIÓN DEL PERFIL DEL SÍNDROME DE LIBERACIÓN DE CITOQUINAS PARA GLOFITAMAB EN COMBINACIÓN CON GEMCITABINA MÁS OXALIPLATINO EN PACIENTES CON LINFOMA DIFUSO DE CÉLULAS B GRANDES EN RECAÍDA/REFRACTARIO (GO45434)

Tipos de enfermedades: Investigación sobre la leucemia y el linfoma

Requisitos de elegibilidad:

Histologically confirmed DLBCL, not otherwise specified (NOS)
R/R disease, defined as: relapsed = disease that has recurred following a response that lasted >/= 6 months after completion of the last line of therapy; refractory = disease that did not respond to or that progressed < 6 months after completion of the last line of therapy
At least one line of prior systemic therapy
Participants who have failed only one prior line of therapy must not be a candidate for high-dose chemotherapy followed by autologous stem cell transplant (ASCT)
At least one bi-dimensionally measurable (> 1.5 cm) nodal lesion, or one bi-dimensionally measurable (> 1 cm) extranodal lesion, as measured on CT scan
Eastern Cooperative Oncology Group (ECOG) status of 0, 1, or 2
Adequate hematologic and renal function

Para más información sobre este juicio , HAGA CLIC AQUÍ.

Disponible en:

• Chesapeake
• Hampton (CarePlex)
• Newport News (Port Warwick III)
• Virginia Beach (Princess Anne)
• Williamsburg
• Norfolk (Centro Oncológico Brock)